Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance

Diabetes

Volumn 60, Issue 5, 2011, Pages 1446-1457

  Mulvihill, Erin E ^a,b   Assini, Julia M ^a,b   Lee, Justin K ^a   Allister, Emma M ^a   Sutherland, Brian G ^a   Koppes, Julie B ^a   Sawyez, Cynthia G ^a,b   Edwards, Jane Y ^a,b   Telford, Dawn E ^a,b   Charbonneau, Alexandre ^c   St Pierre, Philippe ^c   Marette, André ^c   Huff, Murray W ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; CARNITINE PALMITOYLTRANSFERASE I; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; FATTY ACID; GLYCEROL; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NOBILETIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA SINUS; ARTICLE; ATHEROSCLEROSIS; CELL STRAIN HEPG2; CONTROLLED STUDY; DYSLIPIDEMIA; ENERGY EXPENDITURE; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; LIPOPROTEIN SECRETION; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ATHEROSCLEROSIS; BUTADIENES; DIET; DYSLIPIDEMIAS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENERGY METABOLISM; ENZYME INHIBITORS; FLAVONES; HEP G2 CELLS; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIPOPROTEINS, VLDL; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MICE, MUTANT STRAINS; NITRILES; PHOSPHORYLATION; RECEPTOR, INSULIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 79959389136     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0589     Document Type: Article

References (50)

1. Steiner G, Lewis GF. Hyperinsulinemia and triglyceride-rich lipoproteins. Diabetes 1996;45(Suppl. 3):S24-S26
2. Watts GF, Ooi EM, Chan DC. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Pharmacol Ther 2009;123:281-291
3. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106:453-458 (Pubitemid 30666377)
4. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-749
5. Kamagate A, Qu S, Perdomo G, et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008;118: 2347-2364 (Pubitemid 351872351)
6. Verges B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis 2010;211:353-360
7. Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996;37:439-447 (Pubitemid 26134353)
8. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005;36: 232-240 (Pubitemid 40755136)
9. Fisher SJ, Kahn CR. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest 2003;111:463-468 (Pubitemid 36228003)
10. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-1131 (Pubitemid 34496588)
11. Grefhorst A, Parks EJ. Reduced insulin-mediated inhibition of VLDL secretion upon pharmacological activation of the liver X receptor in mice. J Lipid Res 2009;50:1374-1383
12. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008;7:125-134 (Pubitemid 351168555)
13. Han S, Liang CP, Westerterp M, et al. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice. J Clin Invest 2009;119:1029-1041
14. Tsai J, Qiu W, Kohen-Avramoglu R, Adeli K. MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly. Arterioscler Thromb Vasc Biol 2007;27: 211-218 (Pubitemid 46360401)
15. Stefanovic-Racic M, Perdomo G, Mantell BS, Sipula IJ, Brown NF, O'Doherty RM. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am J Physiol Endocrinol Metab 2008;294:E969-E977
16. Atherton HJ, Gulston MK, Bailey NJ, et al. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse. Mol Syst Biol 2009;5:259
17. Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999;98:115-124 (Pubitemid 29331201)
18. Kurowska EM, Manthey JA. Hypolipidemic effects and absorption of citrus polymethoxylated flavones in hamsters with diet-induced hypercholesterolemia. J Agric Food Chem 2004;52:2879-2886
19. Kurowska EM, Spence JD, Jordan J, et al. HDL-cholesterol-raising effect of orange juice in subjects with hypercholesterolemia. Am J Clin Nutr 2000; 72:1095-1100
20. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes 2005;54:1676-1683 (Pubitemid 40770757)
21. Allister EM, Mulvihill EE, Barrett PH, Edwards JY, Carter LP, Huff MW. Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor. J Lipid Res 2008;49:2218-2229
22. Borradaile NM, de Dreu LE, Huff MW. Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes 2003;52:2554-2561 (Pubitemid 37210545)
23. Kurowska EM, Manthey JA. Regulation of lipoprotein metabolism in HepG2 cells by citrus flavonoids. Adv Exp Med Biol 2002;505:173-179 (Pubitemid 34526434)
24. Mulvihill EE, Allister EM, Sutherland BG, et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes 2009;58: 2198-2210
25. Lee YS, Cha BY, Saito K, et al. Nobiletin improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice. Biochem Pharmacol 2010;79: 1674-1683
26. Do GM, Kwon EY, Kim HJ, et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008; 374:55-59
27. Loke WM, Proudfoot JM, Hodgson JM, et al. Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction. Arterioscler Thromb Vasc Biol 2010;30:749-757
28. Mulvihill EE, Assini JM, Sutherland BG, et al. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed lowdensity lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 2010;30:742-748
29. Borradaile NM, Carroll KK, Kurowska EM. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin. Lipids 1999;34:591-598 (Pubitemid 29314429)
30. Patel H, Truant R, Rachubinski RA, Capone JP. Activity and subcellular compartmentalization of peroxisome proliferator-activated receptor alpha are altered by the centrosome-associated protein CAP350. J Cell Sci 2005; 118:175-186 (Pubitemid 40282547)
31. Huss JM, Torra IP, Staels B, Giguère V, Kelly DP. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol 2004;24:9079-9091 (Pubitemid 39313912)
32. Borradaile NM, de Dreu LE, Barrett PH, Behrsin CD, Huff MW. Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry 2003;42:1283-1291 (Pubitemid 36184069)
33. Beyea MM, Heslop CL, Sawyez CG, et al. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J Biol Chem 2007;282:5207-5216 (Pubitemid 47093759)
34. Siri P, Candela N, Zhang YL, et al. Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity, and insulin resistance. J Biol Chem 2001;276:46064-46072
35. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 2006;55:390-397 (Pubitemid 43343268)
36. Charbonneau A, Marette A. Inducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice: potential role of tyrosine nitration of insulin signaling proteins. Diabetes 2010;59:861-871
37. Merat S, Casanada F, Sutphin M, Palinski W, Reaven PD. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler Thromb Vasc Biol 1999;19:1223-1230 (Pubitemid 29227641)
38. Kumar A, Middleton A, Chambers TC, Mehta KD. Differential roles of extracellular signal-regulated kinase-1/2 and p38(MAPK) in interleukin-1beta- and tumor necrosis factor-alpha-induced low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 1998;273:15742-15748 (Pubitemid 28298194)
39. Singh RP, Dhawan P, Golden C, Kapoor GS, Mehta KD. One-way cross-talk between p38(MAPK) and p42/44(MAPK). Inhibition of p38(MAPK) induces low density lipoprotein receptor expression through activation of the p42/ 44(MAPK) cascade. J Biol Chem 1999;274:19593-19600
40. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005;25: 2170-2176 (Pubitemid 41416317)
41. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344-1351 (Pubitemid 40022716)
42. An J, Muoio DM, Shiota M, et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med 2004;10:268-274
43. Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997;46:983-988 (Pubitemid 27220998)
44. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006; 119(Suppl. 1):S10-S16
45. Petersen KF, Shulman GI. New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy. Obesity (Silver Spring) 2006;14(Suppl. 1):34S-40S
46. Ide T, Tsunoda M, Mochizuki T, Murakami K. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice. Med Sci Monit 2004;10:BR388-BR395
47. Kalaany NY, Gauthier KC, Zavacki AM, et al. LXRs regulate the balance between fat storage and oxidation. Cell Metab 2005;1:231-244 (Pubitemid 43960607)
48. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009;4:113-119
49. Lin N, Sato T, Takayama Y, et al. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol 2003;65:2065-2071 (Pubitemid 36629589)
50. Whitman SC, Kurowska EM, Manthey JA, Daugherty A. Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages. Atherosclerosis 2005;178:25-32 (Pubitemid 39600812)